» Articles » PMID: 32761175

Baicalein Attenuates Neuroinflammation by Inhibiting NLRP3/caspase-1/GSDMD Pathway in MPTP Induced Mice Model of Parkinson's Disease

Overview
Specialty Psychiatry
Date 2020 Aug 8
PMID 32761175
Citations 66
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Inflammasome-induced neuroinflammation is a major pathogenic mechanism underlying the degeneration of nigral dopaminergic neurons in Parkinson's disease (PD). Baicalein is a flavonoid isolated from the traditional Chinese medicinal herbal Scutellaria baicalensis Georgi with known anti-inflammatory and neuroprotective efficacy in models of neurodegenerative diseases, including PD. However, its effects on inflammasome-induced neuroinflammation during PD remain unclear.

Methods: We used N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to induce PD-like pathology in mice. Behavioral assessments including the pole test, rotarod test and open filed test were conducted to evaluate the effects of baicalein on MPTP-induced motor dysfunction. The efficacies of baicalein against MPTP-induced dopaminergic neuron loss and glial cell activation in the substantia nigra compact (SNc) were examined by immunohistochemistry, effects on proinflammatory cytokines by qPCR and enzyme-linked immunosorbent assay (ELISA), effects on inflammasome pathway activation by immunoblotting and flow cytometry.

Results: Administration of baicalein reversed MPTP-induced motor dysfunction, loss of dopaminergic neurons, and pro-inflammatory cytokine elevation. Baicalein also inhibited NLRP3 and caspase-1 activation and suppressed gasdermin D (GSDMD)-dependent pyroptosis. Additionally, baicalein inhibited the activation and proliferation of disease-associated proinflammatory microglia.

Conclusions: These findings suggest that baicalein can reverse MPTP-induced neuroinflammation in mice by suppressing NLRP3/caspase-1/GSDMD pathway. Our study provides potential insight of baicalein in PD therapy.

Citing Articles

Promising Natural Remedies for Alzheimer's Disease Therapy.

Thawabteh A, Ghanem A, AbuMadi S, Thaher D, Jaghama W, Karaman D Molecules. 2025; 30(4).

PMID: 40005231 PMC: 11858286. DOI: 10.3390/molecules30040922.


Mitigating neurodegenerative diseases: the protective influence of baicalin and baicalein through neuroinflammation regulation.

Yang R, Wang R, Xu A, Zhang J, Ma J Front Pharmacol. 2024; 15:1425731.

PMID: 39687298 PMC: 11647303. DOI: 10.3389/fphar.2024.1425731.


Effects of Baicalein Pretreatment on the NLRP3/GSDMD Pyroptosis Pathway and Neuronal Injury in Pilocarpine-Induced Status Epilepticus in the Mice.

Kang J, Mo S, Shu X, Cheng S eNeuro. 2024; 12(1.

PMID: 39662962 PMC: 11728850. DOI: 10.1523/ENEURO.0319-24.2024.


Integrated analysis of single-cell RNA sequencing and bulk transcriptome data identifies a pyroptosis-associated diagnostic model for Parkinson's disease.

Wang L, Qin Y, Song J, Xu J, Quan W, Su H Sci Rep. 2024; 14(1):28548.

PMID: 39558055 PMC: 11574289. DOI: 10.1038/s41598-024-80185-9.


A comprehensive review of natural compounds and their structure-activity relationship in Parkinson's disease: exploring potential mechanisms.

Merghany R, El-Sawi S, Naser A, Ezzat S, Moustafa S, Meselhy M Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39392484 DOI: 10.1007/s00210-024-03462-4.


References
1.
Zhou Y, Lu M, Du R, Qiao C, Jiang C, Zhang K . MicroRNA-7 targets Nod-like receptor protein 3 inflammasome to modulate neuroinflammation in the pathogenesis of Parkinson's disease. Mol Neurodegener. 2016; 11:28. PMC: 4833896. DOI: 10.1186/s13024-016-0094-3. View

2.
LeWitt P, Fahn S . Levodopa therapy for Parkinson disease: A look backward and forward. Neurology. 2016; 86(14 Suppl 1):S3-12. DOI: 10.1212/WNL.0000000000002509. View

3.
Zella M, Metzdorf J, Ostendorf F, Maass F, Muhlack S, Gold R . Novel Immunotherapeutic Approaches to Target Alpha-Synuclein and Related Neuroinflammation in Parkinson's Disease. Cells. 2019; 8(2). PMC: 6406239. DOI: 10.3390/cells8020105. View

4.
Fan Z, Pan Y, Zhang Z, Yang H, Yu S, Zheng Y . Systemic activation of NLRP3 inflammasome and plasma α-synuclein levels are correlated with motor severity and progression in Parkinson's disease. J Neuroinflammation. 2020; 17(1):11. PMC: 6950934. DOI: 10.1186/s12974-019-1670-6. View

5.
Ising C, Heneka M . Functional and structural damage of neurons by innate immune mechanisms during neurodegeneration. Cell Death Dis. 2018; 9(2):120. PMC: 5833757. DOI: 10.1038/s41419-017-0153-x. View